Why Moderna (MRNA) rose 14.56%
Moderna (MRNA) rose 14.56% on October 9, 2026 — Nasdaq-100 inclusion hopes and melanoma data fuel call.
What happened
Moderna's options activity surged as traders piled into calls on hopes for Nasdaq-100 inclusion and on melanoma data expectations, pushing the stock up 13%.
Why it moved
Call buying creates its own momentum: dealers hedge short-gamma exposure by buying shares, which amplifies the upside.
Why it matters
Moderna is a high-beta name inside the Healthcare & Biotech theme, where prices are driven by pipeline catalysts rather than current earnings, so flow-driven spikes are common.
What would break the thesis
If the Nasdaq-100 inclusion doesn't materialize or the melanoma data disappoints, the call-driven premium unwinds quickly.